A Clinical Study of Ifosfamide/Mesna and Cisplatin in Recurrent Epithelial Ovarian Cancer.

Shim, Jae Ho; Jang, Kyung Taek; Choi, Kyung Jun; Kim, Hyun Seung; Sunwoo, Jae Kun; Bae, Dong Han

Search: Korean J Obstet Gynecol Search

CLOSE

Original Article

Korean Journal of Obstetrics & Gynecology 1997;40(11):2500-2505.
Published online January 1, 2001.

A Clinical Study of Ifosfamide/Mesna and Cisplatin in Recurrent Epithelial Ovarian Cancer.

Jae Ho Shim, Kyung Taek Jang, Kyung Jun Choi, Hyun Seung Kim, Jae Kun Sunwoo, Dong Han Bae

Department of Obstetrics and Gynecology, Chunan Hospital, College of Medicine, Soonchunhyang University, Korea.

Abstract

This study was planned to evaluate the efficacy and toxicity of fosfamide/mesna plus cisplatin combined regimen in patients with recurrent and initial therapy-resistant epithelial ovarian cancer. Controversy still remains over the efficacy of cisplatin containing combined chemotherapy as the treatment of recurrent ovarian cancer and refractory to first line chemotherapy. Ifosfamide(isophosphamide) is an analog of cyclophosphamide. It has shown evidences of activity in ovarian cancer and lack of cross-resistance with cyclophosphamide. This study was undertaken for the clinical analysis and evaluation on 16 patients, who were admitted and treated with advanced or recurrent ovarian cancer at the Sooncheunhyang University Chunan Hospital from January 1994 to July 1996. The results were as follows: 1. The mean age of patients was 62 year old with range from 44 to 72. 2. The most frequent side effect was nausea and vomiting(75%), followed by leukocytopenia(68%), alopecia(44%), nephrotoxicity(37%), neurotoxicity(25%), and hepatotoxicity(12%). 3. The mean survival period was 24 months in clinical response cases ranged from 11 months to 36 months, 5 months in progressive cases ranged from 1 month to 14 months. 4. In clinical stages, stage II was 6 cases(37.5%), III was 6 cases(37.5%) and IV was 4 cases(25%). 5. Previously all patients were received debulking surgery and PAC hemotherapy. 6. Overall respons rate was 44%(7/16).

Key Words: Recurrent epithelial ovarian cancer, Ifosfomide

TOOLS

Full text via DOI
Download Citation

Share :

METRICS

830 View
10 Download

Related articles in Obstet Gynecol Sci

A clinical evaluation of CA 125 antigen values in patients of ovarian cancer.1991 December;34(12)

Clinical significance of CA 125 in epithelial ovarian carcinoma.1992 January;35(1)

An immunohistochemical evaluation of c-erbB-2 expression in epithelial ovarian cancer.1993 August;36(8)

Clinical study on lymphocyte immunization in recurrent abortion.1993 November;36(11)

A Clinical Study on the Incompetent Internal Os of the Cervix.1997 January;40(1)

ABOUT

ARTICLE & TOPICS

Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES

POLICY

FOR CONTRIBUTORS

Editorial Office: 4th Floor, 36 Gangnam-daero 132-gil, Gangnam-gu, Seoul 06044, Korea.
Tel: +82-2-2266-7238 Fax: +82-2-3445-2440 E-mail: journal@ogscience.org